With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical ...

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The ...

Aurobindo Pharma’s revenue was in-line with our estimates ... We revise our rating to “BUY” from “ACCUMULATE” based on the ...

In order to enhance share liquidity and expand the number of investors trading in the companys shares, Sudarshan Pharma ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...